Minerva Neurosciences Finds No Safety Concerns in Roluperidone-Olanzapine Trial, Phase 3 Underway
Minerva Neurosciences’ open-label trial co-administering roluperidone with olanzapine demonstrated no clinically significant adverse effects or PK/PD changes. The Phase 3 confirmatory study is now enrolling patients, with topline efficacy and safety data expected in the second half of 2027.
1. Open-Label Safety Trial Results
The open-label study evaluated coadministration of roluperidone and olanzapine in patients with moderate to severe negative symptoms of schizophrenia and found no clinically significant adverse effects or meaningful pharmacokinetic or pharmacodynamic interactions across the dosing regimen.
2. Phase 3 Confirmatory Study
Following the favorable safety profile, the Phase 3 confirmatory trial has commenced patient enrollment targeting the same patient population, with topline efficacy and safety data anticipated in the second half of 2027.
3. Strategic Outlook and Impact
Positive safety data reduces development risk and paves the way for pivotal efficacy evaluation, supporting Minerva’s clinical-stage pipeline and enhancing potential value creation upon successful Phase 3 outcomes.